We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ono and Medarex Enter into Second Antibody Development Collaboration
News

Ono and Medarex Enter into Second Antibody Development Collaboration

Ono and Medarex Enter into Second Antibody Development Collaboration
News

Ono and Medarex Enter into Second Antibody Development Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ono and Medarex Enter into Second Antibody Development Collaboration "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ono Pharmaceutical Co., Ltd. and Medarex, Inc. have announced that they have entered into a collaborative agreement to research and develop a fully human anti-SDF-1 antibody for the potential treatment of multiple indications.

This is the second antibody development collaboration between Ono and Medarex. Anti-SDF-1 antibodies have been raised utilizing Medarex's UltiMAb Human Antibody Development System®.

Under this collaboration, Ono and Medarex expect to jointly work toward potential commercialization of a fully human antibody.

The two companies plan to share the costs and responsibilities of research and product development up to the completion of a Phase II clinical study.

Thereafter, each company will be fully responsible for any continued development and any commercialization in its exclusive territory; Medarex's exclusive territory is North America, and Ono's exclusive territory is all areas outside of North America.

"We are pleased to work with Ono as we continue to develop MDX-1106, our anti-PD1 antibody product candidate, and now for the development of a potential anti-SDF-1 antibody product candidate," said Dr. Donald L. Drakeman, President and CEO of Medarex.

Advertisement